BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Arumakimig readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Arumakimig\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07203001-11265@assetmemo.bio
DTSTAMP:20261121T004107Z
DTSTART;VALUE=DATE:20270422
DTEND;VALUE=DATE:20270423
SUMMARY:Arumakimig: Phase 2 readout est. (NCT07203001)
DESCRIPTION:Arumakimig\, phase 2\, Still's Disease.\nStudy: A Phase II Tria
 l to Evaluate the Clinical Efficacy\, Safety and Tolerability of MAS825 in
  Pediatric and Adult Participants With Still's Disease\nEstimated primary 
 completion: 22 April 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/arumakimig#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07203001
URL:https://assetmemo.bio/drug/arumakimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07748624-11265@assetmemo.bio
DTSTAMP:20261121T004107Z
DTSTART;VALUE=DATE:20281226
DTEND;VALUE=DATE:20281227
SUMMARY:Arumakimig: Phase 2 readout est. (NCT07748624)
DESCRIPTION:Arumakimig\, phase 2.\nStudy: A 52-Week Study Evaluating the Ef
 ficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Follow
 ed by Open-Label Extension (OLE) Period\nEstimated primary completion: 26 
 December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/arumak
 imig#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07748624
URL:https://assetmemo.bio/drug/arumakimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
